多発性硬化症患者におけるリツキシマブ誘発性血清病:症例報告と文献レビュー
Asmae Sikkal1, Salma Ouahmane1, Hicham El Otmani1,2
1Department of Neurology and Clinical Neurophysiological Explorations, Ibn Rochd University Hospital of Casablanca, Casablanca, MAR.
Abstract:
Rituximab is a chimeric anti-CD20 monoclonal antibody that is becoming increasingly used in multiple sclerosis. In rare cases, rituximab may induce a delayed immune-mediated reaction such as rituximab-induced serum sickness. We report the case of a 49-year-old woman with multiple sclerosis who developed rituximab-induced serum sickness characterized by fever, diffuse rash, lymphadenopathy, and arthralgia nine days after her first rituximab infusion. We reviewed the number of cases in a literature review, discussing their characteristics and mechanisms and the implications for using alternative anti-CD20 monoclonal antibodies such as ocrelizumab or ofatumumab for the management of multiple sclerosis.
さらに関連する動画
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
10:27Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
関連する概念動画
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Hypersensitivity Reactions: Immune-Complex Reactions
Rheumatic Heart Disease I: Introduction
